Keywords: PharmaMar, Centocor Ortho, Yondelis, Zeltia, Sarcoma, Ovarian cancer

PharmaMar/Centocor’s Yondelis gets five new approvals outside the European Economic Area

Article | 17 March 2010

Print This

Centocor Ortho Biotech Products, a Johnson & Johnson subsidiary that has licensed rights in certain markets for Yondelis (trabectedin) from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in